Back
Also listed as
AMBBY
OTC
Day Range
$13.00
$13.65
52-Week Range
$12.75
$19.35
Volume
600
50D / 200D Avg
$13.40
/
$14.32
Prev Close
$13.65
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 6.0 | 0.4 |
| P/B | 0.6 | 2.9 |
| ROE % | 10.5 | 3.7 |
| Net Margin % | 10.1 | 3.8 |
| Rev Growth 5Y % | 10.7 | 10.0 |
| D/E | 0.1 | 0.2 |
Key Takeaways
Revenue grew 10.70% annually over 5 years — strong growth
Earnings grew 158.66% over the past year
ROE of 10.46% — decent returns on equity
Debt/Equity of 0.09 — conservative balance sheet
Generating 672.72M in free cash flow
P/E of 6.02 — trading at a low valuation
Growth
Revenue Growth (5Y)
10.70%
Revenue (1Y)11.78%
Earnings (1Y)158.66%
FCF Growth (3Y)87.18%
Quality
Return on Equity
10.46%
ROIC8.93%
Net Margin10.09%
Op. Margin12.99%
Safety
Debt / Equity
0.09
Current Ratio2.72
Interest Coverage26.13
Valuation
P/E Ratio
6.02
P/B Ratio0.61
EV/EBITDA4.27
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 11.78% | Revenue Growth (3Y) | 12.34% |
| Earnings Growth (1Y) | 158.66% | Earnings Growth (3Y) | 90.21% |
| Revenue Growth (5Y) | 10.70% | Earnings Growth (5Y) | 25.25% |
| Profitability | |||
| Revenue (TTM) | 6.03B | Net Income (TTM) | 607.84M |
| ROE | 10.46% | ROA | 7.94% |
| Gross Margin | 55.97% | Operating Margin | 12.99% |
| Net Margin | 10.09% | Free Cash Flow (TTM) | 672.72M |
| ROIC | 8.93% | FCF Growth (3Y) | 87.18% |
| Safety | |||
| Debt / Equity | 0.09 | Current Ratio | 2.72 |
| Interest Coverage | 26.13 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 6.02 | P/B Ratio | 0.61 |
| P/S Ratio | 0.61 | PEG Ratio | 0.27 |
| EV/EBITDA | 4.27 | Dividend Yield | 0.00% |
| Market Cap | 3.66B | Enterprise Value | 3.34B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.03B | 5.39B | 4.78B | 4.44B | 4.01B |
| Net Income | 607.84M | 235.00M | 168.00M | 93.00M | 247.00M |
| EPS (Diluted) | 2.28 | 0.88 | 0.64 | 0.37 | 0.98 |
| Gross Profit | 3.37B | 3.20B | 2.71B | 2.55B | 2.50B |
| Operating Income | 782.51M | 645.00M | 302.00M | -26.00M | 340.00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 7.66B | 7.15B | 6.86B | 7.22B | 5.74B |
| Total Liabilities | 1.64B | 1.56B | 1.47B | 2.95B | 1.79B |
| Shareholders' Equity | 6.02B | 5.59B | 5.39B | 4.26B | 3.95B |
| Total Debt | 545.96M | 558.00M | 584.00M | 1.85B | 823.00M |
| Cash & Equivalents | 864.35M | 615.00M | 157.00M | 187.00M | 64.00M |
| Current Assets | 3.15B | 2.64B | 2.01B | 2.30B | 1.61B |
| Current Liabilities | 1.16B | 1.06B | 942.00M | 1.16B | 980.00M |
Strategy Scores
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026
Entered
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered
Defensive Investing (Benjamin Graham)
Mar 24, 2026